Document is current
Any future updates will be listed below
-
Authors
Ogungbe, Oluwabunmi
Grant, Jelani K.
Ayoola, Adeoluwa Segilola
Bansah, Eyram
Miller, Hailey N.
Plante, Timothy B.
Sheikhattari, Payam
Commodore-Mensah, Yvonne
Turkson-Ocran, Ruth-Alma N.
Juraschek, Stephen P.
Martin, Seth S.
Lin, Michael
Himmelfarb, Cheryl R.
Michos, Erin D. https://orcid.org/0000-0002-5547-5084
-
Funding
Funding for this research was provided by:
American Heart Association (946222, 23DIVSUP1058257, 20SFRN35380046, 20SFRN35490003, 882415)
National Center for Advancing Translational Sciences (UL1 TR003098)
National Institute on Minority Health and Health Disparities (P50MD017348-01)
- License Information
-
More Information
Article History
Accepted: 13 August 2023
First Online: 3 October 2023
Compliance with Ethical Standards
:
: Dr. Michos has served as a consultant for Amgen, Amarin, AstraZeneca, Bayer, Boehringer Ingelheim, Edwards Life Science, Esperion, Medtronic, Novartis, Novo Nordisk, and Pfizer and is on an advisory board for Care Access. Under a license agreement between Corrie Health and the Johns Hopkins University, the University owns equity in Corrie Health and the University and Dr. Martin are entitled to royalty distributions related to the Corrie technology. Additionally, Dr. Martin is a co-founder of and holds equity in Corrie Health. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies. Furthermore, Dr. Martin is on the Advisory Board for Care Access and reports personal consulting fees from Amgen, AstraZeneca, Chroma, Kaneka, NewAmsterdam, Novartis, Novo Nordisk, Sanofi, and 89bio. Michael Lin is co-founder of and holds equity in Reify Health. The other authors have nothing to disclose.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
